Surmodics, Inc. (NASDAQ:SRDX) Stake Decreased by White Pine Capital LLC

White Pine Capital LLC lessened its holdings in shares of Surmodics, Inc. (NASDAQ:SRDX) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,343 shares of the company’s stock after selling 1,932 shares during the period. White Pine Capital LLC’s holdings in Surmodics were worth $1,503,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in SRDX. Panagora Asset Management Inc. bought a new stake in shares of Surmodics during the third quarter valued at approximately $683,000. Los Angeles Capital Management LLC increased its stake in shares of Surmodics by 149.2% during the third quarter. Los Angeles Capital Management LLC now owns 34,916 shares of the company’s stock valued at $1,120,000 after acquiring an additional 20,906 shares during the period. Acadian Asset Management LLC increased its stake in shares of Surmodics by 18.8% during the third quarter. Acadian Asset Management LLC now owns 354,738 shares of the company’s stock valued at $11,377,000 after acquiring an additional 56,012 shares during the period. Vanguard Group Inc. increased its stake in shares of Surmodics by 2.4% during the third quarter. Vanguard Group Inc. now owns 846,164 shares of the company’s stock valued at $27,153,000 after acquiring an additional 19,635 shares during the period. Finally, Moody National Bank Trust Division increased its stake in shares of Surmodics by 14.8% during the fourth quarter. Moody National Bank Trust Division now owns 10,341 shares of the company’s stock valued at $376,000 after acquiring an additional 1,331 shares during the period. Institutional investors own 96.63% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on SRDX shares. StockNews.com lowered shares of Surmodics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $47.00 price target on shares of Surmodics in a research report on Wednesday, April 10th.

Surmodics Price Performance

Shares of NASDAQ:SRDX remained flat at $26.17 during trading on Friday. 22,671 shares of the company’s stock were exchanged, compared to its average volume of 105,795. The firm has a market cap of $372.66 million, a price-to-earnings ratio of 68.87 and a beta of 1.01. Surmodics, Inc. has a 52 week low of $16.79 and a 52 week high of $39.41. The company has a fifty day simple moving average of $28.77 and a two-hundred day simple moving average of $31.68. The company has a current ratio of 4.84, a quick ratio of 3.97 and a debt-to-equity ratio of 0.24.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).